At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 330 enrolled
Drug / intervention
Botulinum toxin, Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multi-center, Randomized, Double Blind, Placebo-controlled, Single Dose, Trial to Demonstrate the Safety and Efficacy of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines
In Brief
A Phase 3 clinical trial evaluating Botulinum toxin, Type A and 0.9% sterile, unpreserved saline for Glabellar Frown Lines. Completed, enrolled 330 participants across 1 site.
Detailed Summary
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesUnited States
CollaboratorsPPD Development, LP
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedJan 2015
Primary CompletionDec 2015
TodayJul 2026
First PostedJan 8, 2015
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.5 years ago
Interventions
Botulinum toxin, Type Abiological
Botulinum toxin, Type A
0.9% sterile, unpreserved salineother
Placebo